// App-Quantinova.ai

Filters

Biomarkers











Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease











Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























1151 Abstracts

Apremilast: a Potential Treatment for Dermatomyositis.

Carole Bitar - American Academy of Dermatology (AAD) , 2018

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

N/A

Hydroxychloroquine

Lower eyelid involvement as the unique manifestation of discoid lupus erythematosus

Laura Costamilan - American Academy of Dermatology (AAD) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

Hydroxychloroquine

Darier-Roussy Disease

Albert Antonyan - American Academy of Dermatology (AAD) , 2018

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

N/A

Hydroxychloroquine

Lupus profundus in a patient with undiagnosed systemic lupus erythematosus and “Mechanic’s hands”

Kirsten Webb - American Academy of Dermatology (AAD) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

Hydroxychloroquine

A rare case of Pansclerotic Morphea

Caroline Lee - American Academy of Dermatology (AAD) , 2018

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

N/A

Hydroxychloroquine

Bullous Systemic Lupus Erythematosus in a 17-year-old African American Female

Nikesh Patel - American Academy of Dermatology (AAD) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

Hydroxychloroquine

A Phase 2 Study of Safety and Efficacy of Anabasum (JBT-101), a Cannabinoid Receptor Type 2 Agonist, in Refractory Skin-Predominant Dermatomyositis

Victoria P. Werth - American College of Rheumatology (ACR) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

Hydroxychloroquine

Antimalarial Drug Toxicities in Rheumatic Skin Disease Patients

Lavanya Mittal - American College of Rheumatology (ACR) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

Hydroxychloroquine

Apremilast in Patients with Lupus Rashes

Robert S. Katz - American College of Rheumatology (ACR) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

Hydroxychloroquine

Artesunate Inhabits Migration and Invasion of Fibroblast-like Synoviocytes and Matrix Metalloproteinases Expression Via Suppression of PI3K/Akt Pathway in Rheumatoid Arthritis

Jian-Da Ma - American College of Rheumatology (ACR) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

Hydroxychloroquine

Arthritis and Hydroxychloroquine Are Associated with Decreased Risk of Macrophage Activation Syndrome Among Adults Hospitalized with SLE

Kristin D'Silva - American College of Rheumatology (ACR) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

Hydroxychloroquine

Association between Hydroxychloroquine Nonadherence and Adverse Outcomes Among Patients with Systemic Lupus Erythematosus

Candace H. Feldman - American College of Rheumatology (ACR) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

Hydroxychloroquine

Body Mass Index and Persistence of Conventional Dmards and TNF Inhibitors in Rheumatoid Arthritis

Caroline McCulley - American College of Rheumatology (ACR) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Hydroxychloroquine

Clinical Audit of Hydroxychloroquine Dosing and Toxicity Screening in Patients with Inflammatory Arthritis and Connective Tissue Diseases

Sahil Koppikar - American College of Rheumatology (ACR) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

Hydroxychloroquine

Compliance and Persistence with Hydroxychloroquine in Patients with Systemic Lupus Erythematosus

Seong-Min Kweon - American College of Rheumatology (ACR) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

Hydroxychloroquine

Concomitant Hydroxychloroquine Impact on Anti-TNF Persistence in Patients with Rheumatoid Arthritis

Ming Zhao - American College of Rheumatology (ACR) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

Hydroxychloroquine

Dermatomyositis Acute Onset/Flares Following Ingestion of Isalean® Herbal Supplement: Clinical and Immunostimulatory Findings

Majid Zeidi - American College of Rheumatology (ACR) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

Hydroxychloroquine

Dosechecker: Solving the Hydroxychloroquine Dosing Dilemma with a Smart Phone App

Elliot Perlman - American College of Rheumatology (ACR) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Hydroxychloroquine

Early Exposure to Hydroxychloroquine Predicts Good Renal Response in Japanese Patients with Lupus Nephritis Class III or IV

Tomofumi Kiyokawa - American College of Rheumatology (ACR) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

Hydroxychloroquine

Early Treatment with Hydroxychloroquine Is Associated with Better Long-Term Outcomes in a Group of Hispanic Patients with Rheumatoid Arthritis

Franchesca Cruz-P�rez - American College of Rheumatology (ACR) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

Hydroxychloroquine

Copyright © 2026. QuantiNova All rights reserved